Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial
In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier
The FDA approved a label update for Merck's WINREVAIR medicine. The update shows the drug helps newer PAH patients when added to other treatments.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.